| |
| Names | |
|---|---|
| Other names
| |
| Identifiers | |
3D model (JSmol) |
|
| ChemSpider | |
| MeSH | C516441 |
PubChem CID |
|
| |
| |
| Properties | |
| C6H12O21P6 | |
| Molar mass | 605.984 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
myo-Inositol trispyrophosphate (ITPP) is an inositol phosphate, a pyrophosphate, a drug candidate, and a putative performance-enhancing substance, which exerts its biological effects by increasing tissue oxygenation.[1]
ITPP is a pyrophosphate derivativeofphytic acid with the molecular formula C6H12O21P6.[1]
ITPP is a membrane-permeant allosteric regulatorofhemoglobin that mildly reduces its oxygen-binding affinity, which shifts the oxygen-hemoglobin dissociation curve to the right and thereby increases oxygen release from the blood into tissue.[1] Phytic acid, in contrast, is not membrane-permeant due to its charge distribution.[1]
Rodent studies in vivo demonstrated increased tissue oxygenation and dose-dependent increases in endurance during physical exercise, in both healthy mice and transgenic mice expressing a heart failure phenotype.[1]
The substance is believed to have a high potential for use in athletic doping, and liquid chromatography–mass spectrometry tests have been developed to detect ITPP in urine tests.[2] Its use as a performance-enhancing substance in horse racing has also been suspected and similar tests have been developed for horses[3]
ITPP has been studied for potential adjuvant use in the treatment of cancer in conjunction with chemotherapy, due to its effects in reducing tissue hypoxia.[4] Human clinical trials were registered in 2014 under the compound number OXY111A.[5] The substance has also been examined in the context of other illnesses involving hypoxia, such as cardiovascular disease and dementia[2]
